In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)The Japanese yen faces new risks. Strategists worry that the Bank of Japan may wait until March or later to raise interest rates. A new risk is emerging for the Japanese yen. Foreign exchange strategists in Tokyo warn that the Bank of Japan may wait until March or later next year to raise interest rates. On Wednesday, the market tasted this danger, and the yen fell to its lowest level in more than two weeks as traders responded to a Bloomberg report that the Bank of Japan is known to think that it is no harm to raise interest rates later. The yen only fell to 152.82 against the dollar, and the market is still debating whether the Bank of Japan will take action at its next meeting on December 19 or about a month later. Shusuke Yamada, head of Japan's foreign exchange and interest rate strategy at Bank of America in Tokyo, said that if policymakers put off raising interest rates for a longer time, the situation would be very different. "If the interest rate hike is postponed until March, the yen carry trade is likely to make a comeback," Yamada said on Thursday. "The yen is likely to fall again to a level just below the 157 mark hit in 155 or November."President of the Swiss National Bank: We will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. The president of the Swiss National Bank said that we will continue to monitor inflationary pressure and adjust monetary policy to maintain price stability if necessary. If there is no interest rate cut today, inflation expectations will be lower; The uncertainty of the future inflation path is still high.
The attack on the headquarters of the Ministry of Refugees and Repatriation in Afghanistan killed four people. An official from the Ministry of Interior of the Afghan Interim Government said on the 11th that the suicide attack at the headquarters of the Ministry of Refugees and Repatriation that day killed four people and seriously injured four others. Mufti Abdul Martin Carney, spokesman of the Interior Ministry of the Afghan interim government, issued a statement on the 11th, confirming that Khalil Rahman Haqqani, Acting Minister of Refugee and Repatriation Affairs, was killed in the attack. Haqqani is one of the leading figures of the Taliban in Afghanistan, and also the uncle of sirajuddin Haqqani, Acting Minister of the Interior of the Afghan Interim Government. (Xinhua News Agency)Ai Kelan: The actual controller intends to transfer 5% shares of the company by agreement. Ai Kelan announced that Liu Yi, the controlling shareholder and actual controller of the company, intends to transfer 4 million unrestricted shares of the company to Guangdong Nanchuan Private Equity Fund Management Co., Ltd. by agreement transfer, accounting for 5.00% of the company's total share capital. If the transaction is finally completed, Liu Yi holds 33.89% of the company's shares, and Nanchuan Private Equity holds 5.00% of the company's shares. This change in equity will not lead to changes in the controlling shareholder and actual controller of the company. The transfer of shares in this agreement can only be handled in Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. after the compliance confirmation of Shenzhen Stock Exchange. The share transfer price of this transaction is 20.61 yuan/share.Lingang Daya Auto Parts Intelligent Manufacturing Base Project officially started. On the morning of December 12th, the groundbreaking ceremony of Lingang Daya Auto Parts Intelligent Manufacturing Base Project was held in Shanghai Lingang Fengxian Park. After the completion of the project, two 3500T/2500T high-speed multi-position stamping lines are designed, with an annual production capacity of 11 million pieces; Design 210 connection workstations such as spot welding/arc welding/projection welding/riveting, with an annual production capacity of 4 million sets of sheet metal parts; Design an intelligent logistics and three-dimensional warehouse.
Zelensky's office stated that it was ready to negotiate with Russia. Mikhail Podolyak, adviser to the director of Ukrainian President Zelensky's office, said in an interview with Channel 24 that Kiev was ready to negotiate with Russia. He pointed out that simple solutions should not be expected, and Ukraine needs just peace conditions. Earlier, Kremlin spokesman dmitry Peskov said that Russia was willing to negotiate with Ukraine provided that the conditions proposed by Russian President Vladimir Putin were met. The conditions mentioned include the complete withdrawal of Ukrainian troops from new Russian regions and Ukraine's neutrality.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.Market information: The major shareholders of Hershey, an American chocolate manufacturer, will reject the takeover proposal of Yizi International, thinking that the other party's offer is too low.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
12-13